Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab
Part of paid clinical trials in Augusta, Georgia.
- Sponsor
- Southeast Retina Center, Georgia
- Study ID
- NCT01845844
- Phase
- PHASE1/PHASE2
- Status
- Unknown
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Ranibizumab 0.3mg/0.05cc — DRUGGroup A (Arm A) will receive monthly 0.3mg/0.05cc intravitreal injections for 12 consecutive months. Group B (Arm B) will receive monthly 0.3mg/0.05cc intravitreal injections for the first six months and then PRN for the remaining 6 months per protocol specified criteria.
Study Details
This is an open-label, Phase I/II study of Intravitreally administered 0.3mg ranibizumab in subjects with persistent Diabetic Macular Edema (DME) after recent and frequent bevacizumab (at least 2 bevacizumab intravitreal injections within 2 months prior to enrollment and at least 6 bevacizumab injections within 9 months of enrollment).
Key Dates
- First listed
- May 3, 2013
- Start date
- Apr 30, 2013
- Status verified
- Sep 2014
- Primary completion
- Jan 31, 2015
- Completion
- Jan 31, 2015
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Ranibizumab 0.3mg (12 months)Intravitreal injection of ranibizumab 0.3mg/0.05cc
- Active Comparator: Ranibizumab 0.3mg (6 months)Intravitreal injection of ranibizumab 0.3mg/0.05cc
Primary Outcome Measure
Incidence of ocular and systemic adverse events will be compared between experimental and active comparator groups [ Time Frame: 1 year ]
Central Contacts
- Dennis M Marcus, M.D.706-650-0061
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Southeast Retina Center, PC | Augusta | Georgia | 30909 | Dennis M Marcus, M.D. (PRINCIPAL_INVESTIGATOR) Harinderjit Singh, M.D. (SUB_INVESTIGATOR) |
Find similar trials in Augusta, GA
By condition
By specialty
By research site
Related Studies
- COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEPHASE3 · Recruiting · EyePoint Pharmaceuticals, Inc. · Bakersfield, California
- Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)PHASE1 · Recruiting · Ocugen · Deerfield Beach, Florida
- EC-104 Intravitreal Implant for the Treatment of Diabetic Macular EdemaPHASE1/PHASE2 · Recruiting · Eclipse Life Sciences, Inc. · Tampa, Florida
- Intranasal Delivery of Octreotide for Treatment of Diabetic Macular EdemaPHASE1 · Not Yet Recruiting · University of Alabama at Birmingham · Birmingham, Alabama